Keyword: University of California San Diego
An enzyme that works on leptin receptors and a receptor protein called MC3R could be anti-obesity drug targets.
The past week ushered in news about a toxin in scorpion venom that may relieve RA and a skin bacterium with anti-cancer powers.
Biotech news over the last week included a reversible sealant to shore up eye injuries and a promising gene therapy for the immune disorder known as "bubble boy" disease.
Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.
J&J has unveiled another clutch of deals and collaborations with industry and academia.
An international team may have found an alternative approach to managing peripheral neuropathy that could potentially reverse symptoms with a class of drugs already in use for other conditions.
Researchers have found that the role of cancer-promoting and cancer-inhibiting enzymes is more complex than previously thought.
A UC San Diego-led team studying chronic inflammation and Type 2 diabetes has discovered that removing the protein galectin-3 from mice can reverse the insulin resistance and glucose intolerance that come with diabetes and obesity.
Researchers have recently found a key player that might be regulating an important immune system process, and by blocking this molecule they can increase the sensitivity of a tumor to anticancer drugs.
UC San Diego biochemists have identified patterns in the surface protein of group A Streptococcus. The findings could result in a vaccine for the bacteria, which can cause life-threatening disease, including toxic shock syndrome and necrotizing fasciitis, or “flesh-eating disease.”